RET in breast cancer: pathogenic implications and mechanisms of drug resistance

Abstract

Initiation, progression, outcome and sensibility to therapies in breast cancer (BC), the most frequent cancer in women, are driven by somatic and germline mutations. Although the effectiveness of hormonal therapies is well-founded, it is prescribed for cancers which express steroid hormone receptors, such as estrogen receptor (ER). RET is a proto-oncogene encoding a transmembrane tyrosine kinase receptor that is activated by one of its four ligands (GDNF, neurturin, artemin or persephin) and one of its coreceptors (Gfrα1-4). Loss-of-function mutations in RET are responsible for Hirschsprung disease, while gain-of-function mutations for multiple endocrine neoplasia type 2. In addition, deregulation of its intracellular signaling, due to mutations, gene rearrangements, overexpression or transcriptional upregulation, can cause several neuroendocrine and epithelial tumors. In BC, amplification of receptor tyrosine kinases, such as ERBB2, EGFR, IGFR and FGFR1, and/or their upregulation contribute to cancer initiation and progression. RET can also have an important role in BC, but only in the subset of ER-positive (ER+) tumors, where it is found overexpressed. Targeting the RET pathway and shedding light on molecular basis of the resistance to hormone therapy may lead to new therapies in ER+ BC, improving treatment outcome and preventing tumor-related events. Thus, here, we review the state of the art of RET biology in BC and agents targeting RET tested in the clinical trials and discuss the specificity of the still available RET inhibitors and the molecular mechanisms underlying the BC resistance to endocrine therapy.

Keywords

Breast cancer / RET / hormone resistance / receptor tyrosine kinases inhibitors

References

[1] Jemal A,Center MM,Ward E.Global cancer statistics..CA Cancer J Clin2011;61:69-90

[2] Tao Z,Lu C,Zhang Z.Breast cancer: epidemiology and etiology..Cell Biochem Biophys2015;72:333-8

[3] Anastasiadi Z,Ignatiadou E,Mitsis M.Breast cancer in young women: an overview..Updates Surg2017;69:313-17

[4] van der Groep P,van Diest PJ.Pathology of hereditary breast cancer..Cell Oncol (Dordr)2011;34:71-88 PMCID:PMC3063560

[5] Shiovitz S.Genetics of breast cancer: a topic in evolution..Ann Oncol2015;26:1291-9 PMCID:PMC4478970

[6] Watson IR,Futreal PA.Emerging patterns of somatic mutations in cancer..Nat Rev Genet2013;14:703-18 PMCID:PMC4014352

[7] Bertheau P,Varna M,Poirot B.p53 in breast cancer subtypes and new insights into response to chemotherapy..Breast.2013;22 Suppl 2:S27-9

[8] Goncalves R,Luo J.New concepts in breast cancer genomics and genetics..Breast Cancer Res2014;16:460 PMCID:PMC4384360

[9] Byler S,Heerboth S,Housman G.Genetic and epigenetic aspects of breast cancer progression and therapy..Anticancer Res2014;34:1071-7

[10] Spanheimer PM,De Andrade JP,Carr JC.Receptor tyrosine kinase expression predicts response to sunitinib in breast cancer..Ann Surg Oncol2015;22:4287-94 PMCID:PMC5003404

[11] Sorlie T,Tibshirani R,Geisler S.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications..Proc Natl Acad Sci USA2001;98:10869-74 PMCID:PMC58566

[12] Spanheimer PM,Thomas A,Scott-Conner CE.The response to neoadjuvant chemotherapy predicts clinical outcome and increases breast conservation in advanced breast cancer..Am J Surg2013;206:2-7 PMCID:PMC3644520

[13] Rouzier R,Symmans WF,Cristofanilli M.Breast cancer molecular subtypes respond differently to preoperative chemotherapy..Clin Cancer Res2005;11:5678-85

[14] Meyers MO,Ollila DW,Moore DT.Impact of breast cancer molecular subtypes on locoregional recurrence in patients treated with neoadjuvant chemotherapy for locally advanced breast cancer..Ann Surg Oncol2011;18:2851-7

[15] Livi L,Saieva C,Nori J.Breast cancer in the elderly: treatment of 1500 patients..Breast J2006;12:353-59

[16] Huang B,Gustafsson JA.Estrogen receptors in breast carcinogenesis and endocrine therapy..Mol Cell Endocrinol2015;418:240-4

[17] Brufsky AM.Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer..Am J Clin Oncol2014;37:404-10 PMCID:PMC4162320

[18] Morandi A,Gao Q,Mackay A.GDNF-RET signaling in ER-positive breast cancers is a key determinant of response and resistance to aromatase inhibitors..Cancer Res2013;73:783-95 PMCID:PMC3686594

[19] Forbes JF,Buzdar A,Tobias JS.Effect of anastrozole and tamoxifenas adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial..Lancet Oncol2008;9:45-53

[20] Winer EP,Burstein HJ,Pritchard KI.American society of clinical oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004..J Clin Oncol2005;23:619-29

[21] Bousquet G,Ferreira I,Mongiat-Artus P.Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and/or tumor cell apoptosis..Cancer Chemother Pharmacol2013;72:1183-93

[22] Aparicio-Gallego G,Figueroa A,Valladares-Ayerbes M.New insights into molecular mechanisms of sunitinib-associated side effects..Mol Cancer Ther2011;10:2215-23

[23] Kudo M.Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice..Int J Clin Oncol2010;15:242-55

[24] Lei JT,Seker S.ESR1 alterations and metastasis in estrogen receptor positive breast cancer..J Cancer Metastasis Treat2019;5:38 PMCID:PMC6519472

[25] Arpino G,Osborne CK.Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance..Endocr Rev2008;29:217-33 PMCID:PMC2528847

[26] Martin LA,Johnston SR,Marshall C.Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation..J Biol Chem2003;278:30458-68

[27] Stephen RL,Larsen C,Darbre PD.Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells..J Biol Chem2001;276:40080-6

[28] Miller TW,Gonzalez-Angulo AM,Mills GB.Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer..J Clin Invest2010;120:2406-13 PMCID:PMC2898598

[29] Nayar U,Kapstad C,Waks AG.Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies..Nat Genet2019;51:207-16

[30] Zabransky DJ.Estrogen receptor and receptor tyrosine kinase signaling: use of combinatorial hormone and epidermal growth factor receptor/human epidermal growth factor receptor 2-targeted therapies for breast cancer..J Clin Oncol2014;32:1084-6

[31] Plaza-Menacho I,Sala E,Magee AI.Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting..J Biol Chem2007;282:29230-40

[32] Gschwind A,Ullrich A.The discovery of receptor tyrosine kinases: targets for cancer therapy..Nat Rev Cancer2004;4:361-70

[33] Griseri P,Lo Sardo A,Rusmini M.Genetic and epigenetic factors affect RET gene expression in breast cancer cell lines and influence survival in patients..Oncotarget2016;7:26465-79 PMCID:PMC5041993

[34] Airaksinen MS,Saarma M.GDNF family neurotrophic factor signaling: four masters, one servant?.Mol Cell Neurosci1999;13:313-25

[35] Arighi E,Sariola H.RET tyrosine kinase signaling in development and cancer..Cytokine Growth Factor Rev2005;16:441-67

[36] Mulligan LM.RET revisited: expanding the oncogenic portfolio..Nat Rev Cancer2014;14:173-86

[37] Raue F.update on multiple endocrine neoplasia type 2: focus on medullary thyroid carcinoma..J Endocr Soc2018;2:933-43 PMCID:PMC6065486

[38] Dionigi G,Rovera F,Piantanida E.Medullary thyroid carcinoma: surgical treatment advances..Expert Rev Anticancer Ther2007;7:877-85

[39] Wells SA Jr,Robinson BG.Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update..J Clin Endocrinol Metab2013;98:3149-64 PMCID:PMC5399478

[40] Toledo SPA,Toledo RA.Impact of RET proto-oncogene analysis on the clinical management of multiple endocrine neoplasia type 2..Clinics2006;61:59-70

[41] Moura MM,Pinto AE,Santos JR.Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas..Br J Cancer2009;100:1777-83 PMCID:PMC2695700

[42] Dvorakova S,Sykorova V,Novak Z.Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas..Mol Cell Endocrinol2008;284:21-7

[43] Elisei R,Romei C,Renzini G.Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study..J Clin Endocrinol Metab2008;93:682-7

[44] Kurzrock R,Ball DW,Cohen RB.Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer..J Clin Oncol2011;29:2660-6 PMCID:PMC3646303

[45] Santoro M,Fusco A.RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture..Eur J Endocrinol2006;155:645-53

[46] Ciampi R.RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis..Endocrinology2007;148:936-41

[47] Subbiah V,Rahal R,Kim JL.Precision targeted therapy with BLU-667 for RET-driven cancers..Cancer Discov2018;8:836-49

[48] Kato S,Marchlik E,Carter JL.RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients..Clin Cancer Res2017;23:1988-97

[49] Ballerini P,Cresson C,Toujani S.RET fusion genes are associated with chronic myelomonocytic leukemia and enhance monocytic differentiation..Leukemia2012;26:2384-9

[50] Gozgit JM,Song Y,Wang F.RET fusions observed in lung and colorectal cancers are sensitive to ponatinib..Oncotarget2018;9:29654-64 PMCID:PMC6049858

[51] Mulligan LM.GDNF and the RET receptor in cancer: new insights and therapeutic potential..Front Physiol2019;9:1873 PMCID:PMC6330338

[52] Skálová A,Santana T,Ihrler S.NCOA4-RET and TRIM27-RET are characteristic gene fusions in salivary intraductal carcinoma, including invasive and metastatic tumors: is “Intraductal” correct?.Am J Surg Pathol2019;43:1303-13

[53] Wiesner T,Yelensky R,Botton T.Kinase fusions are frequent in Spitz tumours and spitzoid melanomas..Nat Commun2014;5:3116 PMCID:PMC4084638

[54] Paratala BS,Williams CB,Petrosky W.RET rearrangements are actionable alterations in breast cancer..Nat Commun2018;9:4821 PMCID:PMC6240119

[55] Griseri P,Puppo F,Ravazzolo R.A common haplotype at the 5’ end of the RET proto-oncogene, overrepresented in Hirschsprung patients, is associated with reduced gene expression..Hum Mutat2005;25:189-95

[56] Emison ES,Kashuk CS,Grice E.A common sex-dependent mutation in a RET enhancer underlies Hirschsprung disease risk..Nature2005;434:857-63

[57] Lantieri F,Puppo F,Martucciello G.Haplotypes of the human RET proto-oncogene associated with Hirschsprung disease in the Italian population derive from a single ancestral combination of alleles..Ann Hum Genet2006;70:12-26

[58] Borun P,Ziemnicka K,Lipinski D.Absence of the RET+3:T allele in the MTC patients..Hered Cancer Clin Pract2012;10:14 PMCID:PMC3533580

[59] Emison ES,Grice EA,Amiel J.Differential contributions of rare and common, coding and noncoding Ret mutations to multifactorial Hirschsprung disease liability..Am J Hum Genet2010;87:60-74 PMCID:PMC2896767

[60] Morandi A,Isacke CM.RET in breast cancer: functional and therapeutic implications..Trends Mol Med2011;17:149-57

[61] Tozlu S,Vacher S,Andrieu C.Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach..Endocr Relat Cancer2006;13:1109-20

[62] Esseghir S,Hunt T,Plaza-Menacho I.A role for glial cell derived neurotrophic factor induced expression by inflammatory cytokines and RET/GFR alpha 1 receptor up-regulation in breast cancer..Cancer Res2007;67:11732-41

[63] Boulay A,Stephan C,Brisken C.The Ret receptor tyrosine kinase pathway functionally interacts with the ERalpha pathway in breast cancer..Cancer Res2008;68:3743-51

[64] Plaza-Menacho I,Robertson D,Drury S.Targeting the receptor tyrosine kinase RET sensitizes breast cancer cells to tamoxifen treatment and reveals a role for RET in endocrine resistance..Oncogene2010;29:4648-57

[65] Gattelli A,Boulay A,Schreiber M.Ret inhibition decreases growth and metastatic potential of estrogen receptor positive breast cancer cells..EMBO Mol Med2013;5:1335-50 PMCID:PMC3799490

[66] Nguyen M,Kato J,Arai T.Preclinical efficacy and safety assessment of an antibody-drug conjugate targeting the c-RET proto-oncogene for breast carcinoma..Clin Cancer Res2015;21:5552-62

[67] Drosten M.Mechanisms of disease: cancer targeting and the impact of oncogenic RET for medullary thyroid carcinoma therapy..Nat Clin Pract Oncol2006;3:564-74

[68] Plaza-Menacho I,de Groot JW,Hofstra RM.Current concepts in RET-related genetics, signaling and therapeutics..Trends Genet2006;22:627-36

[69] Lanzi C,Nicolini V.Targeting RET for thyroid cancer therapy..Biochem Pharmacol2009;77:297-309

[70] Scott RP,Aineskog H.Distinct turnover of alternatively spliced isoforms of the RET kinase receptor mediated by differential recruitment of the Cbl ubiquitin ligase..J Biol Chem2005;280:13442-29

[71] Hickey JG,Tian X,V Shaw JL.RET-mediated gene expression pattern is affected by isoform but not oncogenic mutation..Genes Chromosomes Cancer2009;48:429-40

[72] Le Hir H,de Franciscis V.5’-End RET splicing: absence of variants in normal tissues and intron retention in pheochromocytomas..Oncology2002;63:84-91

[73] Ferlay J,Dikshit R,Mathers C.Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012..Int J Cancer2015;136:E359-86

[74] Yuan ZL,Wang L,Kane AB.Central role of the threonine residue within the p+1 loop of receptor tyrosine kinase in STAT3 constitutive phosphorylation in metastatic cancer cells..Mol Cell Biol2004;24:9390-400 PMCID:PMC522220

[75] Borrello MG,Locati LD,Licitra L.RET inhibition: implications in cancer therapy..Expert Opin Ther Targets2013;17:403-19

[76] de Groot JW,Schepers H,Osinga J.Cellular effects of imatinib on medullary thyroid cancer cells harboring multiple endocrine neoplasia type 2A and 2B associated RET mutations..Surgery2006;139:806-14

[77] Pacifico F,Mellone S,Porrino N.Nuclear factor-{kappa}B contributes to anaplastic thyroid carcinomas through up-regulation of miR-146a..J Clin Endocrinol Metab2010;95:1421-30

[78] Castellone MD,Rao DM,Muthu M.The beta-catenin axis integrates multiple signals downstream from RET/papillary thyroid carcinoma leading to cell proliferation..Cancer Res2009;69:1867-76 PMCID:PMC2746012

[79] Plaza-Menacho I,Barry R,Orme M.RET functions as a dual-specificity kinase that requires allosteric inputs from juxtamembrane elements..Cell Rep2016;17:3319-32 PMCID:PMC5199340

[80] Uhlen M,Lee S,Fagerberg L.A pathology atlas of the human cancer transcriptome..Science2017;357:eaan2507

[81] Spanheimer PM,Askeland RW,Woodfield GW.Inhibition of RET increases the efficacy of anti-estrogen and is a novel treatment strategy for luminal breast cancer..Clin Cancer Res2014;20:2115-25 PMCID:PMC3989441

[82] Sommer S.Estrogen receptor and breast cancer..Semin Cancer Biol2001;11:339-52

[83] Stine ZE,Bessling SL,McCallion AS.Steroid hormone modulation of RET through two estrogen responsive enhancers in breast cancer..Hum Mol Genet2011;20:3746-56 PMCID:PMC3168285

[84] Spanheimer PM,Cyr AR,White-Baer LS.Expression of the RET proto-oncogene is regulated by TFAP2C in breast cancer independent of the estrogen receptor..Ann Surg Oncol2013;20:2204-12 PMCID:PMC3697477

[85] Wang C,Mazumdar A.The rearranged during transfection/papillary thyroid carcinoma tyrosine kinase is an estrogen dependent gene required for the growth of estrogen receptor positive breast cancer cells..Breast Cancer Res Treat2012;133:487-500 PMCID:PMC3424514

[86] Tan SK,Chang CW,Chng KR.AP-2 regulates oestrogen receptor-mediated long-range chromatin interaction and gene transcription..EMBO J2011;30:2569-81 PMCID:PMC3155293

[87] Williams T.Analysis of the DNA-binding and activation properties of the human transcription factor AP-2..Genes Dev1991;5:670-82

[88] McPherson LA.AP2alpha and AP2gamma: a comparison of binding site specificity and trans-activation of the estrogen receptor promoter and single site promoter constructs..Nucleic Acids Res1999;27:4040-9 PMCID:PMC148672

[89] De Andrade JP,Gu VW,Kulak MV.EGFR is regulated by TFAP2C in luminal breast cancer and is a target for Vandetanib..Mol Cancer Ther2016;15:503-11 PMCID:PMC4783288

[90] Hatem R,Château-Joubert S,El Botty R.Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers..Int J Cancer2016;138:2510-21

[91] de Groot JW,van Ufford-Mannesse PQ,Links TP.A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma..J Clin Endocrinol Metab2007;92:3466-9

[92] Phay JE.Targeting RET receptor tyrosine kinase activation in cancer..Clin Cancer Res2010;16:5936-41

[93] Polverino A,Starnes C,DeMelfi T.AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts..Cancer Res2006;66:8715-21

[94] Caenepeel S,Baher A,Baron W.Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors..J Exp Clin Cancer Res2010;29:96 PMCID:PMC2912835

[95] McPherson LA.AP2alpha and AP2gamma: a comparison of binding site specificity and trans-activation of the estrogen receptor promoter and single site promoter constructs..Nucleic Acids Res1999;27:4040-9 PMCID:PMC148672

[96] Plaza-Menacho I,Mologni L,Gambacorti-Passerini C.Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism..J Biol Chem2011;286:17292-302 PMCID:PMC3089571

[97] Mulligan LM.RET revisited: expanding the oncogenic portfolio..Nat Rev Cancer2014;14:173-86

[98] Spanheimer PM,Gillum MP,Askeland RW.Distinct pathways regulated by RET and estrogen receptor in luminal breast cancer demonstrate the biological basis for combination therapy..Ann Surg2014b;259:793-9 PMCID:PMC3986044

[99] Li L,Jiao S,Zhang F.Vandetanib (ZD6474) induces antiangiogenesis through mTOR-HIF-1 alpha-VEGF signaling axis in breast cancer cells..Onco Targets Ther2018;11:8543-53 PMCID:PMC6278704

[100] Zhang M,Chen WL,Nie JY.Opposite response to hypoxia by breast cancer cells between cell proliferation and cell migration: a clue from microRNA expression profile..Oncol Lett2018;15:2771-80 PMCID:PMC5778814

[101] Kapinova A,Zubor P,Dankova Z.The hypoxia-responsive long non-coding RNAs may impact on the tumor biology and subsequent man¬agement of breast cancer..Biomed Pharmacother2018;99:51-8

[102] Wilhelm SM,Tang L,McNabola A.BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis..Cancer Res2004;64:7099-109

[103] Carlomagno F,Guida T,Troncone G.BAY 43-9006 inhibition of oncogenic RET mutants..J Natl Cancer Inst2006;98:326-34

[104] Kim DW,Jung HS,Song JH.An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases..J Clin Endocrinol Metab2006;91:4070-6

[105] Karaman MW,Treiber DK,Atteridge CE.A quantitative analysis of kinase inhibitor selectivity..Nat Biotechnol2008;26:127-32

[106] Wedge SR,Dukes M,Chester R.ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration..Cancer Res2002;62:4645-55

[107] Wells SA Jr,Gagel RF,Pfister D.Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer..J Clin Oncol2010;28:767-72 PMCID:PMC2834392

[108] Herbst RS,O’Reilly MS,Ryan AJ.Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis..Expert Opin Investig Drugs2007;16:239-49

[109] Andreucci E,Fearns A,Chiarugi P.Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts..Oncotarget2016;7:80543-53 PMCID:PMC5348339

[110] Ackermann CJ,Tay R,Gomes F.Targeted therapy for RET-rearranged non-small cell lung cancer: clinical development and future directions..Onco Targets Ther2019;12:7857-64 PMCID:PMC6767757

[111] Iams WT.Stop fRETting the target: next-generation RET inhibitors have arrived..Cancer Discov2018;8:797-9 PMCID:PMC6345252

[112] Drilon A,Patel MR,Wang D.A phase I/Ib trial of the VEGFR sparing multikinase RET inhibitor RXDX-105..Cancer Discov2019;9:384-95 PMCID:PMC6397691

[113] Morandi A.Targeting RET-interleukin-6 crosstalk to impair metastatic dissemination in breast cancer..Breast Cancer Res2014;16:301 PMCID:PMC3978856

[114] Forbes JF,Buzdar A,Tobias JS.Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial..Lancet Oncol2008;9:45-53

[115] Ali S.Endocrine-responsive breast cancer and strategies for combating resistance..Nat Rev Cancer2002;2:101-12

[116] Massarweh S.Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk..Endocr Relat Cancer.2006;13 Suppl 1:S15-24

[117] Musgrove EA.Biological determinants of endocrine resistance in breast cancer..Nat Rev Cancer2009;9:631-43

[118] Martin LA,Johnston SR,Marshall C.Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation..J Biol Chem2003;278:30458-68

[119] Martin LA,Chan CM,Kimberley C.The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling..Endocr Relat Cancer2005;2:1017-36

[120] Musgrove EA.Biological determinants of endocrine resistance in breast cancer..Nat Rev Cancer2009;9:631-43

[121] Ma CX,Chmielewska I.Mechanisms of aromatase inhibitor resistance..Nat Rev Cancer2015;15:261-75

[122] Chung YL,Yang SC,Yen SH.Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer..Int J Cancer2002;97:306-12

[123] Osborne CK,Massarweh S.Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer..Clin Cancer Res2005;11:865s-70

[124] Shou J,Osborne CK,Ali S.Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer..J Natl Cancer Inst2004;96:926-35

[125] Shou J,Osborne CK,Ali S.Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer..J Natl Cancer Inst2004;96:926-35

[126] Pancholi S,Hilmi C,Leary A.ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2..Endocr Relat Cancer2008;15:985-1002

[127] Benz CC,Sarup JC,Tripathy D.Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu..Breast Cancer Res Treat1992;24:85-95

[128] Yamashita H.Current research topics in endocrine therapy for breast cancer..Int J Clin Oncol2008t;13:380-3

[129] Kok M,Hauptmann M,Stål O.Estrogen receptor-alpha phosphorylation at serine-118 and tamoxifen response in breast cancer..J Natl Cancer Inst2009;101:1725-9

[130] Gardaneh M,Kaviani A.GDNF induces RET-SRC-HER2-dependent growth in trastuzumab-sensitive but SRC-independent growth in resistant breast tumor cells..Breast Cancer Res Treat2017;162:231-41

[131] Slamon DJ,Shak S,Paton V.Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2..N Engl J Med2001;344:783-92

[132] Marty M,Maraninchi D,Mauriac L.Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group..J Clin Oncol2005;23:4265-74

[133] Hurtado A,Geistlinger TR,Nicholson RI.Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen..Nature2008;456:663-6 PMCID:PMC2920208

[134] Horibata S,Mukai C,Sams K.ER-positive breast cancer cells are poised for RET-mediated endocrine resistance..PLoS One2018;13:e0194023 PMCID:PMC5880349

[135] Kuno R,Nitta A,Wang J.The role of TNF-alpha and its receptors in the production of NGF and GDNF by astrocytes..Brain Res2006;1116:12-8

[136] O’Reilly KE,She QB,Mills GB.mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt..Cancer Res2006;66:1500-8 PMCID:PMC3193604

[137] Sariola H.Novel functions and signalling pathways for GDNF..J Cell Sci2003;116:3855-62

[138] Drosten M.Mechanisms of disease: cancer targeting and the impact of oncogenic RET for medulary thyroid carcinoma therapy..Nat Clin Pract Oncol2006;3:564-74

[139] Hickey JG,Tian X,Shaw JL.RET-mediated gene expression pattern is affected by isoform but not oncogenic mutation..Genes Chromosomes Cancer2009;48:429-40

[140] Emison ES,Grice EA,Amiel J.Differential contributions of rare and common, coding and noncoding Ret mutations to multifactorial Hirschsprung disease liability..Am J Hum Genet2010;87:60-74 PMCID:PMC2896767

[141] Sorlie T,Tibshirani R,Geisler S.Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications..Proc Natl Acad Sci U S A2001;98:10869-74 PMCID:PMC58566

[142] Williams T.Analysis of the DNA-binding and activation properties of the human transcription factor AP-2..Genes Dev1991;5:670-82

[143] Woodfield GW,Bair TB,Weigel RJ.Identification of primary gene targets of TFAP2C in hormone responsive breast carcinoma cells..Genes Chromosomes Cancer2010;49:948-62 PMCID:PMC2928401

[144] Ma CX,Ellis MJ.Predicting endocrine therapy responsiveness in breast cancer..Oncology (Williston Park)2009;23:133-42

[145] Rosen LS,Chap L.Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review..Oncologist2010;15:216-35 PMCID:PMC3227950